Anti-Müllerian Hormone and Embryo Aneuploidy

The goal of this observational study is to determine is there an association between the rates of aneuploidy and the different ranges of serum Antimullerian hormone (AMH) levels.

Retrospective, single-centre study of patients undergoing IVF and preimplantation genetic testing with aneuploidy at the blastocyst stage between January 2018 and December 2022.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infertility Aneuploidy Chromosome Aberrations Genital Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Urogenital Diseases

Sex eligibility

Female

Study type

Observational

Primary location

Clinica de la Mujer Medicina Reproductiva

Viña del Mar, Valparaiso, 2520187, Chile

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All started cycles planned to be followed by preimplantation genetic testing for aneuploidies (PGT-A). PGT-A is proposed to the couples for the following reasons: advanced maternal age, recurrent miscarriage, repeated implantation failure or severe male infertility factor; it is also offered to all patients with a good prognosis who desired information regarding the ploidy status of their embryos.

Exclusion criteria

Data from oocyte donation cycles

Treatment and study plan

preimplantation genetic test for aneuploidies (PGT-a)

Other

preimplantation genetic test for embryo aneuploidies after IVF

Primary outcomes

Aneuplody rate

Time frame: 4 years

Secondary outcomes

Clinical pregnancy rate

Time frame: 4 years
Miscarriage rate

Time frame: 4 years

Sponsors and collaborators

Lead sponsor

Clinica de la Mujer Medicina Reproductiva, Chile

Other

Registry information

Official study title

Serum Anti-Müllerian Hormone Levels and Its Association With Aneuploidy Rates in Human Blastocysts

Important dates

Study start: 2018
Primary completion: 2022
Study completion: 2022
First posted: Feb 10, 2023
Registry last updated: Feb 10, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed